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Objectives: Diagnosing thromboembolic disease typically includes 
d-dimer testing and use of clinical scores in patients with low to in-
termediate pretest probability. However, renal dysfunction is often 
observed in patients with thromboembolic disease and was pre-
viously shown to be associated with increased d-dimer levels. We 
seek to validate previously suggested estimated glomerular filtra-
tion rate–adjusted d-dimer cutoff levels. Furthermore, we strive to 
explore whether the type of renal dysfunction affects estimated 
glomerular filtration rate–adjusted d-dimer test characteristics.
Design: Single-center retrospective data analysis from electronic 
healthcare records of all emergency department patients admitted 
for suspected thromboembolic disease.
Setting: Tertiary care academic hospital.
Subjects: Exclusion criteria were as follows: age less than 16 years 
old, patients with active bleeding, and/or incomplete records.
Interventions: Test characteristics of previously suggested that 
estimated glomerular filtration rate–adjusted d-dimer cutoff lev-
els (> 333 µg/L [estimated glomerular filtration rate, > 60 mL/
min/1.73 m2], > 1,306 µg/L [30–60 mL/min/1.73 m2], and > 
1,663 µg/L [< 30 mL/min/1.73 m2]) were validated and compared 
with the conventional d-dimer cutoff level of 500 µg/L.
Main Results: A total of 14,477 patients were included in the final 
analysis, with 467 patients (3.5%) diagnosed with thromboem-
bolic disease. Renal dysfunction was observed in 1,364 (9.4%) of 
the total population. When adjusted d-dimer levels were applied, 
test characteristics remained stable: negative predictive value 
(> 99%), sensitivity (91.2% vs 93.4%), and specificity (42.7% vs 
50.7%) when compared with the conventional d-dimer cutoff level 
to rule out thromboembolic disease (< 500 µg/L). Comparable 
characteristics were also observed when adjusted d-dimer cutoff 
levels were applied in patients with acute kidney injury (negative 
predictive value, 98.8%; sensitivity, 95.8%; specificity, 39.2%) 
and/or “acute on chronic” renal dysfunction (negative predictive 
value, 98.0%; sensitivity, 92.9%; specificity, 48.5%).
Conclusions: d-Dimer cutoff levels adjusted for renal dysfunction 
appear feasible and safe assessing thromboembolic disease in 
critically ill patients. Furthermore, adjusted d-dimer cutoff levels 
seem reliable in patients with acute kidney injury and “acute on 
chronic” renal dysfunction. In patients with estimated glomer-
ular filtration rate less than 60 mL/min/1.73 m2, the false-positive 
rate can be reduced when estimated glomerular filtration rate–
adjusted d-dimer cutoff levels are applied. (Crit Care Med 2019; 
XX:00–00)
Key Words: deep vein thrombosis; pulmonary embolism; renal 
dysfunction; renal failure; renal insufficiency; thromboembolic 
disease
Thromboembolic disease (TED) often presents with un-specific symptoms (1) and has a high prevalence and mortality (2, 3). Hence, careful diagnostic workup of 
TED is considered paramount (1). Despite ongoing efforts to 
improve the diagnosis of TED, clinical outcomes remained 
rather unchanged during the past decades. Furthermore, hos-
pitalizations due to pulmonary embolism (PE) are rising in 
the United States (1, 2). In patients with low or intermediate 
pretest probability, diagnosis of TED is still based on a com-
bination of clinical scores such as Wells score, revised Geneva 
Score, or Pulmonary Embolism Rule out Criteria score, as well 
as laboratory workup based on a d-dimer assay (1–3). How-
ever, although the sensitivity of d-dimer testing is considered 
good (99%), its specificity remains reduced (about 40–60%) DOI: 10.1097/CCM.0000000000004204
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(2, 4). In daily clinical practice, this results in a considerable 
number of patients in which TED cannot be excluded based 
on routine clinical and laboratory workup (3). Thus, duplex 
sonography of the extremities and/or contrast-based chest CT 
is applied (1, 2). However, respective investigations are costly 
and involve both radiation and contrast media exposure 
which may have detrimental side effects (1, 3). Hence, it seems 
of paramount importance to optimize respective existing di-
agnostic tools.
d-Dimers are proteins that indicate fibrinolysis and reflect 
an activated state of coagulation (3, 5). Problematically, how-
ever, increased levels of d-dimer proteins are considered highly 
unspecific. For example, several confounding factors such as 
age, pregnancy, infections, or liver failure may influence serum 
d-dimer values (1–3). One additional important confounding 
factor with a high prevalence in critical illness is renal dys-
function, as elimination of d-dimer protein partly occurs via 
the kidneys and renal dysfunction is typically associated with 
a state of chronic hypercoagulation (6). Previous studies sug-
gest that there is a strong correlation between the degree of 
renal dysfunction and d-dimer levels (7, 8). Our group recently 
explored the use of renal function–adjusted d-dimer cutoff 
levels in the critically ill patients (8). The aim of the current 
investigation was to validate these findings in a large cohort 
of critically ill patients admitted to a tertiary care academic 
hospital. Furthermore, we seek to investigate characteristics of 
estimated glomerular filtration rate (eGFR)-adjusted d-dimer 
cutoff levels in patients with acute kidney injury and/or “acute 
on chronic” renal dysfunction.
METHODS
Study Site
The Bern University Hospital, Bern, Switzerland (Inselspital), 
is one of the largest hospitals in Switzerland with its emer-
gency department (ED) treat-
ing more than 45,000 patients 
per year.
Study Design and 
Eligibility Criteria
This is a retrospective data 
analysis using anonymized 
data from electronic patient 
charts. Adult patients (defined 
as > 16 yr) admitted to our 
ED with a d-dimer and serum 
creatinine assessment during 
the 4-year study period (Jan-
uary 2014 to December 2017) 
were included. The follow-
ing exclusion criteria applied: 
patients with active bleeding, 
d-dimer assessment greater 
than 24 hours after ED admis-
sion, patients with insufficient 
documentation of International Classification of Diseases, 10th 
Edition (ICD-10) codes and laboratory values (potential rea-
sons include diagnosis not coded by ICD-10 code), missing 
d-dimer value, and/or missing serum creatinine level. A study 
flowchart is shown in Figure 1.
Data Collection and Extraction
Patients were identified through a combined search for 
d-dimer and creatinine testing and emergency admission in 
the hospital database, to identify ED patients admitted for sus-
pected TED. The workup of patients at risk for TED adhered 
to current clinical guidelines that suggest a combination of 
clinical evaluation and d-dimer assessment, complemented 
by radiologic workup, if indicated (3). Respective medical 
records, laboratory findings, diagnoses, and administrative 
data were extracted. The following variables were coded: age, 
sex, race, time between admission and d-dimer testing, serum 
creatinine levels, diagnoses including type of TED and type 
of renal dysfunction (defined as acute, chronic, and/or “acute 
on chronic”), history of TED, history of recent operation and 
immobility, infection, history of cancer, presence of cardiac 
failure, any medication that would influence coagulation cas-
cades, and outcome data (admission to ICU and inhospital 
mortality). Diagnoses were based on ICD-10 coding (9, 10). 
Trained personnel of our hospitals’ medical coding division 
assessed all patients’ medical records including laboratory and 
radiologic findings to code respective diagnoses for each indi-
vidual patient.
d-Dimer Assay
D-dimer levels were assessed by the accredited hemostaseo-
logic laboratory of the University Hospital Bern (testing ma-
trix: citrate). The following test was used: Sysmex CS-5100 
with Innovance D-dimer essay (Siemens Healthcare, Zu-
rich, Switzerland; reference range: < 500 µg/L; sensitivity, 
Figure 1. Study flowchart. ED = emergency department.
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98.9%; specificity, 39.6%; negative predictive value [NPV], 
99.6% [11]).
Serum Creatinine Assessment
Serum creatinine levels were determined from heparinized 
blood at the accredited Center of Laboratory Medicine, Uni-
versity Hospital Bern, by the use of Roche Modular P800 (F. 
Hofmann-La Roche, Basel, Switzerland; reference range: man, 
60–104 µmol/L; woman, 45–84 µmol/L).
Definitions
TED. Patients with evidence for the following diagnoses (based 
on ICD-10 coding) were coded as TED: patients with PE, 
patients with deep venous thrombosis (DVT), and/or others 
(included venous thrombosis of the spleen, thrombosis of the 
vena porta, the vena cava, venous mesenterial thrombosis, and 
sinus venous thrombosis). The category DVT compromised 
DVT of the upper and lower extremities as well as the pelvis.
eGFR Calculation. eGFR was calculated using the Chronic 
Kidney Disease Epidemiology (CKD-EPI) Collaboration For-
mula (12):




= × ( ) × ( )
× ×




0 0  1 18 if woman   1 16  if black. .0 0( ) × ( )
where Scr is the serum creatinine (mg/dL), κ is 0.7 for women 
and 0.9 for men, α is –0.329 for women and –0.411 for men, 
min indicates the minimum of Scr/κ or 1, and max indicates 
the maximum of Scr/κ or 1.
Assessment of Renal (Dys)function. The grading of renal 
function was based on eGFR estimates (see above) (13). 
For this study and in accordance with our previous inves-
tigation (8), a simplified grading system was used to assess 
three key categories of renal dysfunction: eGFR less than 
30 mL/min/1.73 m2 (severe renal dysfunction), eGFR 
30–60 mL/min/1.73 m2 (moderate renal dysfunction), and 
eGFR greater than 60 mL/min/1.73 m2 (normal renal function 
or mild renal dysfunction).
Definition of Renal Dysfunction. The assessment of 
whether a given patient had acute, chronic, and/or “acute on 
chronic” renal dysfunction was based on respective established 
ICD-10 diagnoses. The ICD-10 coding system bases its defi-
nition of chronic kidney disease on the grading by the Renal 
Association (13). The grading in the ICD-10 code for acute 
kidney injury follows the RIFLE criteria (14, 15). Patients with 
“acute on chronic” renal dysfunction were defined as patients 
with a known history of chronic kidney disease with acute 
aggravation.
Comparison of d-Dimer Cutoff Levels
We compared the “conventional” d-dimer cutoff level of 
500 µg/L (3) with the eGFR-adjusted d-dimer cutoff levels as 
previously proposed by our group (8). For adjusted cutoff lev-
els, we used greater than 333 µg/L for the eGFR group greater 
than 60 mL/min/1.73 m2, greater than 1,306 µg/L (eGFR, 
30–60 mL/min/1.73 m2), and greater than 1,663 µg/L (eGFR, 
< 30 mL/min/1.73 m2). Adjusted cutoff levels were calculated 
to obtain a posttest probability of 1%, a widely accepted safety 
benchmark for patients with TED (16).
Ethical Considerations
The study was approved by the competent Ethics Committee 
of the Canton of Bern (Kantonale Ethikkommission [cantonal 
ethics committee (EC) in German]), Switzerland (EC no. 2018-
00560). Individual informed consent was waived by the EC.
Statistical Analysis
Stata 13.1 (StataCorp, The College Station, TX) was used for 
statistical analysis.
For descriptive purposes, medians with interquartile (25–
75th quartile) ranges are given. For continuous variables, abso-
lute values accompanied by the relative number are presented. 
As most variables were not normally distributed, log transfor-
mation and nonparametric testing was applied. The Spearman 
rank correlation test was used to test for a correlation among 
eGFR, serum creatinine levels, and d-dimer levels.
To quantify diagnostic strength, sensitivity/specificity, and 
negative and positive predictive values are given for the un-
adjusted and adjusted d-dimer levels in the respective sub-
groups. A two-tailed p value of less than 0.05 was considered 
significant.
RESULTS
Of 19,116 patients, a total of 14,477 patients were available for 
study inclusion (Fig. 1).
Patient Characteristics
The median age was 64 years (interquartile range [IQR], 
49–77); 52.6% (n = 7,613) of the patients were men. A total of 
467 patients (3.5%) had TED with PE being the most frequent 
presentation of TED (n = 302 [64.6%]). Median d-dimer levels 
were 509 µg/L (IQR, 268–1,196 µg/L) (Table 1). The median 
serum creatinine level was 76.0 µmol/L (IQR, 64–91 µmol/L), 
and the median was eGFR 100 mL/min (IQR, 71–141 mL/min). 
Of respective patients, 82.4% (n = 11,935) presented with 
an eGFR greater than 60 mL/min/1.73 m2. A total of 1,364 
patients (9.4%) had chronic kidney disease; acute kidney in-
jury was present in 228 (1.6%) of all patients. Supplemental 
Digital Table 1 (Supplemental Digital Content 1, http://links.
lww.com/CCM/F284) shows the association of thromboem-
bolia (TE) with baseline/patient characteristics: a significant 
association (p < 0.001) was observed with age, previous TE, 
chronic and acute renal failure, cardiac insufficiency, acute in-
fection, solid and hematologic neoplasia, and prior surgery.
d-Dimer Levels and Renal (Dys)function
Declining eGFR moderately correlated with d-dimer levels 
(Spearman ρ, –0.33; p < 0.0001), whereas creatinine values 
and d-dimer levels correlated weakly (Spearman ρ, 0.22; 
p < 0.0001) (Fig. 2). The association between renal dysfunc-
tion and negative d-dimer values is given in Table 1. With 
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declining renal function, the percentage of patients with a 
d-dimer below the conventional cutoff of less than 500 µg/L 
decreased from 55.1% (eGFR, > 60 mL/min/1.73 m2) to 11.7% 
(eGFR,< 30 mL/min/1.73 m2).
Out of 1,364 patients with acute kidney injury, chronic 
renal failure, or “acute on chronic” renal dysfunction (any 
type), 86.0% of patients had d-dimer levels greater than 500 
µg/L, whereas 9.0% had a thromboembolic event.
Comparison of Test Characteristics
Supplemental Digital Table 2 (Supplemental Digital Content 
2, http://links.lww.com/CCM/F285) indicates test characteris-
tics for the conventional d-dimer cutoff of 500 µg/L and eGFR-
adjusted d-dimer cutoffs. When eGFR-adjusted d-dimer cutoff 
levels are used for TED testing, respective test characteristics 
were considered comparable (NPV 99% and similar sensitivity/
specificity). In patients with eGFR 30–60 mL/min/1.73 m2, the 
number of false positives was reduced by 49.9% (675/1,353), 
whereas in the eGFR group less than 30 mL/min/1.73 m2, this 
number was reduced by 55.8% (278/498) when adjusted cutoff 
values were used.
Sensitivity Analysis
When eGFR-adjusted d-dimer cutoff levels are used in patients 
with acute kidney injury, the NPV remained high (98.8%) with 
a sensitivity of 95.8% and a specificity of 39.2%. The same was 
observed for patients with “acute on chronic” renal dysfunc-
tion, where the use of renal function–adjusted d-dimer values 
showed a sensitivity of 98.0%, a specificity of 48.5% with a 
NPV of 98.0%. Test characteristics for eGFR-related d-dimer 
cutoff levels in patients with acute and/or “acute on chronic” 
renal dysfunction are given (Supplemental Digital Table 2, 
Supplemental Digital Content 2, http://links.lww.com/CCM/
F285). Test characteristics remained comparable when data 
were stratified by gender and age groups (Supplemental Dig-
ital Table 3, Supplemental Digital Content 3, http://links.lww.
com/CCM/F286).
DISCUSSION
This single-center retrospective study aimed to validate previ-
ously suggested eGFR-dependent d-dimer cutoff levels (8) to 
exclude TED in critically ill patients. Furthermore, we aimed 
to evaluate a potential influence of a specific type of renal dys-
function on the ability of adjusted d-dimer cutoff levels to 
exclude patients with TED. We observed that the use of eGFR-
adjusted d-dimer cutoff levels appeared safe to rule out TED in 
critically ill patients admitted for suspected TED. Furthermore, 
an influence of the type of renal dysfunction on test perfor-
mance was not observed.
Apart from previous studies by our group (7, 8), only 
two other studies evaluated the use of renal (dys)function 
on adjusted d-dimer cutoff levels (6, 17). One study investi-
gated 1,784 ED patients with mild to moderate renal dysfunc-
tion (17) and confirmed the safety of renal function–adjusted 
d-dimer thresholds. In contrast, a recently published study 
from Germany involving 1,082 patients questioned the validity 
of renal function–adjusted d-dimer testing in individuals sus-
pected for venous thromboembolism (6). However, the results 
of the latter study may need to be interpreted with caution and 
respective data can likely not be compared with our investi-
gation for several reasons. First, the patient population had 
a rather high prevalence of TED with almost half of the pa-
tient population being diagnosed with TED (6). In contrast, 
our current and previous data may reflect rather typical preva-
lence rates of thromboembolic events of about 2–5% (18–20). 
Second, the data presented in the German trial originated from 
a large prospective study investigating patients with DVT and/
or PE (21). This might have introduced a selection bias as in-
clusion criteria for this study were either “proven” or suspected 
TED, and patients were recruited based on these inclusion cri-
teria on all hospital wards (21). In contrast, we aimed to include 
all patients admitted to the ED with “suspected” thromboem-
bolic events. Third, median d-dimer values were 1,400 µg/L 
(IQR, 3,120 µg/L) in the German study, whereas they were 509 
µg/L (IQR, 928 µg/L) in our study. This may implicate that a 
considerable number of patients with a high pretest probability 
TABLE 1. d-Dimer and Renal (Dys)function








Renal function (mL/min)    
 eGFR > 60 11 935 (82.4) 6,574 (55.1) 353 (3.0)
 eGFR 30–60 1,919 (13.3) 477 (24.9) 94 (4.9)
 eGFR < 30 623 (4.3) 73 (11.7) 53 (8.5)
Renal insufficiency    
 Kidney failure, any type 1,364 (9.4) 191 (14.0) 123 (9.0)
 Chronic kidney failure, any stage 1,253 (8.7) 176 (14.0) 113 (9.0)
 Acute kidney failure, any stage 228 (1.6) 26 (11.4) 24 (10.5)
 Acute on chronic, kidney failure 117 (0.8) 11 (9.4) 14 (11.9)
eGFR = estimated glomerular filtration rate.
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for TED (or proven TED) was likely included in this study co-
hort. d-Dimer testing, independent of whether adjusted or 
conventional cutoff levels were applied, may not be regarded 
optimally suited for a population with a high pretest proba-
bility or in patients already diagnosed with TED (3). Fourth, 
the significantly lower percentage of patients with severe renal 
dysfunction in the German study (2.6% vs 4.6% in our study) 
might hamper comparison and drawing of further conclusions 
as this appeared to be the patient group that might benefit the 
most from adjusted d-dimer cutoff testing.
A particular strength of adjusted cutoff levels may be the 
significant (almost 50%) reduction in the number of false 
positives in the moderate to severe renal dysfunction group. 
This may be considered of major importance, as exposure 
to contrast media used for 
CT-pulmonary angiography 
and resulting associated con-
trast-induced nephropathy 
is regarded of considerable 
prognostic importance in this 
cohort of patients and should 
be avoided whenever pos-
sible (22, 23). eGFR-adjusted 
cutoff levels may also allow for 
exclusion of TED and avoid-
ance of radiologic workup in 
patients with moderate to se-
vere renal dysfunction with a 
low to moderate pretest prob-
ability. Notably, in our popula-
tion, 86% (1,173/1,364) of all 
patients with renal dysfunc-
tion had a d-dimer measure-
ment above the conventional 
d-dimer cutoff of 500 µg/L, 
whereas 9% (123/1,364) of 
those patients effectively suf-
fered from TED. Hence, radia-
tion exposure might be avoided 
and healthcare costs reduced 
when eGFR-adapted d-dimer 
thresholds are applied.
It seems not surprising 
that for patients in the eGFR 
greater than 60 mL/min/1.73 
m2 group, the number of 
false positives rises when the 
adjusted cutoff value of 333 
µg/L is applied compared 
with the conventional cutoff. 
However, as this is a rather 
large cohort of patients, the 
issue of false positives may 
still remain problematic. The 
high number of false positives 
may relate to additional factors 
(other than renal dysfunction) that may influence the coagu-
lation cascade and hence result in increased d-dimer levels in-
cluding age, pregnancy, systemic infection, active malignancy, 
surgery, immobility, or others (6–8, 24–26). Until now, studies 
investigated adjustment for single confounders when evaluat-
ing patient-adjusted d-dimer thresholds. In consideration of 
the complex pathophysiology of d-dimers and many contrib-
uting factors leading to rise in blood levels, the potential of 
adaptation to multiple patient-specific factors seems tempting.
Theoretically, if eGFR-based d-dimer thresholds would 
have been applied in January 2014, further radiologic workup 
might have been omitted in 884 patients, with 18 patients 
theoretically having a delayed or missed diagnosis. However, 
while evaluating new test thresholds, it appears that there 
Figure 2. Correlation between d-dimer/estimated glomerular filtration rate (eGFR) and serum creatinine/d-
dimer. CKD-EPI = Chronic Kidney Disease Epidemiology.
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obviously is inevitable trade-off between false positives and 
false negatives. Due to the potential high mortality associ-
ated with TED, a low safety margin of 1–2% may be deemed 
appropriate (16). Hence, the aim for further improvement 
of d-dimer test characteristics may lie in keeping the safety 
margin while improving test specificity. Individualizing the 
cutoff value based on the patient’s individual attributes (e.g., 
age, pregnancy) and disease profile (e.g., renal dysfunction) 
might considerably reduce the number of false positives in 
patients admitted with TED. Potentially, further “individu-
alizing” of d-dimer thresholds taking into account multiple 
confounding factors for increased d-dimer might improve the 
specificity of (individualized) thresholds while maintaining a 
safety margin of about 1%.
This is the first study to evaluate the use of eGFR-depen-
dent d-dimer thresholds for the exclusion of TED in patients 
with acute and “acute on chronic” renal dysfunction. Hence, 
we evaluated the use of eGFR-adjusted d-dimer cutoff levels 
in these patient groups. Our results imply that eGFR-adjusted 
d-dimer thresholds can be used safely for the exclusion of TED 
in patients admitted with acute or acute on chronic kidney 
disease, provided that eGFR (CKD-EPI) is calculated based 
on serum creatinine levels within 24 hours of ED admission. 
This seems important for clinicians, as baseline eGFR or cre-
atinine values are often not known in patients admitted to the 
ED and thus differentiation among acute, chronic, and “acute 
on chronic” renal dysfunction in a timely manner can be par-
ticularly challenging. Nevertheless, our date indicate that, the 
cutoff levels proposed may be useful independent of the “type” 
of renal dysfunction.
In the future, further research on individualizing d-dimer 
cutoffs should be undertaken to especially increase the accu-
racy in patients later transferred to ICUs. Individual d-dimer 
threshold adjustment based on individual patient profiles 
might be especially suited for complex environments such as 
the ICU. Over time on the ICU, patients often suffer from mul-
tiple comorbidities and currently used “conventional” d-dimer 
thresholds may be limited due to confounders associated with 
critical illness. Special emphasis might be necessary with regard 
to integrating multiple patient-adjusted factors to compute in-
dividual d-dimer thresholds aiming to reduce false positives 
while keeping false-negative rates at 1%. Furthermore, safety 
and feasibility of single- or multiple-factor–adjusted d-dimer 
threshold should be confirmed in prospective, preferably mul-
ticenter studies.
Our study has limitations that warrant discussion. First, 
this is a single-center study and external validity is limited. 
External validity should thus be evaluated in prospective stud-
ies. Furthermore, due to the retrospective study design and 
a large dataset, potential false reporting/false coding and/or 
misclassification may have occurred. Furthermore, the specific 
type of TED that was suspected at ED admission was not avail-
able. Second, a d-dimer test may have been ordered without 
appropriate indication (additional testing), and, by nature of 
the retrospective investigation, documentation errors cannot 
be excluded with certainty. Third, despite the fact that clinical 
scores for assessment of pretest probability are used at our 
ED in daily practice, these could not be assessed electroni-
cally for this big data project and were not evaluated in this 
study. Fourth, this analysis assesses the diagnostic performance 
of eGFR-adjusted d-dimer thresholds in patients with acute, 
chronic, and “acute on chronic” renal dysfunction within the 
first 24 hours of admission. The use of eGFR-adjusted cut-
offs outside this time frame requires further validation and 
should therefore be applied with caution. Fifth, the calculation 
of eGFR is based on the assumption that eGFR would remain 
stable within the first hours after ICU admission in patients 
with TED.
CONCLUSIONS
In a large cohort of critically ill patients with suspected throm-
boembolism, we find that renal (dys)function–adjusted 
d-dimer cutoffs levels appear feasible and safe (when compared 
with conventional d-dimer cutoffs) to assess TED. In patients 
with moderate or severely reduced eGFR (< 60 mL/min/1.73 
m2), the number of false positives can be remarkably reduced 
when adjusted cutoff values are used. Furthermore, our data 
suggest that eGFR-adjusted d-dimer cutoff values appear also 
reliable in patients with acute and/or “acute on chronic” renal 
dysfunction. Confirmatory prospective investigations seem 
warranted.
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